On the other hand, in a prospective clinical trial, Mariano Duarte and colleagues, using the ARB telmisartan in high doses of 160 mg/day vs. standard care in hospitalized patients with COVID-19 not in intensive care before 4 days from the onset of symptoms, report a significant decrease in plasma CRP values in the patients treated with the ARB on days 5 and 8 [19]. Here, CRP is linked to COVID-19.